Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MHA112-PLGA-PEG
- Development stage
- Preclinical
- Lead developer
- Brigham and Women's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
MHA112-PLGA-PEG is a targeted polymeric nanoparticle drug delivery system composed of poly(lactic-co-glycolic acid)-polyethylene glycol (PLGA-PEG) nanoparticles conjugated to MHA112, a novel monoclonal antibody targeting peripheral node addressin (PNAd). PNAd is a family of glycoproteins constitutively expressed on high endothelial venules (HEVs) in lymph nodes and ectopically formed in the stroma of tumors and inflamed tissues. By binding to PNAd, MHA112-PLGA-PEG nanoparticles selectively home to lymph nodes and inflamed sites, enabling targeted delivery of encapsulated therapeutic payloads. In preclinical studies, MHA112-PLGA-PEG nanoparticles carrying anti-IL-6R have been investigated to attenuate ischemia-reperfusion injury (IRI) and improve graft outcomes in cardiac transplantation by limiting effector T cell responses.
- Other names
- MHA112-PEG-PLGAMHA-112-PEG-PLGAMHA 112-PEG-PLGAMHA112-PLGA-PEG NPsMHA-112-PLGA-PEG NPsMHA 112-PLGA-PEG NPsMHA112-PLGA-PEG nanoparticlesMHA-112-PLGA-PEG nanoparticlesMHA 112-PLGA-PEG nanoparticles
02
Targets
PNAd (Peripheral node addressin)
Beyond the preview
Go deeper on MHA112-PLGA-PEG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MHA112-PLGA-PEG.